STOCK TITAN

Tempus AI, Inc - TEM STOCK NEWS

Welcome to our dedicated page for Tempus AI news (Ticker: TEM), a resource for investors and traders seeking the latest updates and insights on Tempus AI stock.

Tempus AI, Inc. (TEM) is a pioneering technology company dedicated to revolutionizing healthcare through its innovative AI-driven solutions. The company has developed the Tempus Platform, a sophisticated technology framework designed to liberate healthcare data from restrictive silos and transform it into actionable insights. This platform is complemented by a robust operating system that ensures the resulting data is not only accessible but also incredibly useful for healthcare providers.

One of Tempus AI's standout features is its Intelligent Diagnostics suite, which leverages advanced AI, including generative AI, to enhance the accuracy, personalization, and effectiveness of laboratory tests. This cutting-edge technology enables more precise diagnostic results, leading to better patient outcomes and more efficient healthcare processes.

The company is continuously working on innovative projects and forging strategic partnerships to expand its impact in the healthcare sector. Recent achievements include significant advancements in AI algorithms and successful integrations with major healthcare systems, further cementing its position as a leader in the field.

Financially, Tempus AI has shown robust growth and maintained a solid economic foundation, attracting the interest of investors and stakeholders alike. The company's performance is closely monitored by analysts, particularly due to its potential to disrupt the healthcare landscape with its state-of-the-art technological solutions.

For investors seeking the latest updates and detailed information about Tempus AI's performance, events, and developments, staying informed through reliable sources is crucial. The company's ongoing projects and recent news reflect its commitment to innovation and excellence in the healthcare technology arena.

Rhea-AI Summary

Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, has announced its plans to report second quarter 2024 financial results on Tuesday, August 6, 2024. The company will hold an earnings conference call at 4:30 p.m. ET on the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers.

Investors and interested parties can access the live audio webcast through the events page of Tempus' Investor Relations website. Alternatively, participants can join the call using the following details:

  • Conference ID: 6326328
  • Domestic Dial-in Number: (800) 715-9871
  • International Dial-in Number: (646) 307-1963
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.18%
Tags
conferences earnings
-
Rhea-AI Summary

Tempus AI (NASDAQ: TEM) has launched its multimodal immune profile score (IPS) algorithmic test for research use only. This pan-cancer test assesses immunotherapy-related biomarkers to calculate an IPS from 0-100, classifying results as IPS-Low or IPS-High. The test aims to support patient stratification for immunotherapy response across pan-cancer cohorts.

Tempus is also collaborating with partners like Cleveland Clinic to expand its immunotherapy-focused algorithmic test portfolio. The company has licensed a machine-learning-based test developed by Dr. Timothy A. Chan at Cleveland Clinic, which predicts immune checkpoint blockade efficacy based on patient-specific factors.

These developments are part of Tempus' growing suite of AI-enabled predictive algorithms, including tests for Homologous Recombination Deficiency, Tumor Origin, and dihydropyrimidine dehydrogenase. The IPS test is expected to be available as an add-on option for clinicians ordering Tempus' xT and xR tests by year-end.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.31%
Tags
AI
-
Rhea-AI Summary

Tempus AI (NASDAQ: TEM) has achieved a significant milestone with over 500 research publications in eight years, emphasizing its commitment to scientific rigor and advancing precision medicine. The company's research portfolio includes 143 peer-reviewed articles, 291 poster presentations, and 31 oral presentations at major scientific conferences. Key forums include the ASCO Annual Meeting and SABCS. Their research supports the clinical validation of Tempus tests, such as HRD and TO, and showcases advancements in genomic sequencing and molecular profiling. CEO Eric Lefkofsky and Senior Strategic Advisor Norman E. Sharpless highlight the importance of Tempus' contributions to biomedical research and clinical care advancements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.45%
Tags
none
Rhea-AI Summary

Tempus AI (NASDAQ: TEM) has received a proprietary laboratory analysis (PLA) code from the American Medical Association (AMA) for its PurISTSM algorithmic test, effective October 1, 2024. PurISTSM analyzes previously sequenced RNA data to classify pancreatic cancer patients into subtypes, aiding first-line therapy decisions. The PLA code marks progress towards reimbursement for AI-driven algorithms. Clinical studies show PurISTSM stratifies overall survival for patients with specific therapies. The AMA's Category I CPT codes for RNA sequencing, effective January 2023, reflect growing recognition of RNA profiling. Major insurers like Medicare and Cigna deem RNA profiling medically necessary. Tempus's xR assay, submitted to the FDA, aims to qualify for ADLT status, facilitating advanced diagnostics and precision therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.51%
Tags
none
-
Rhea-AI Summary

Tempus AI (NASDAQ: TEM) has been awarded Advanced Diagnostic Laboratory Test (ADLT) status by the Centers for Medicare & Medicaid Services (CMS) for its FDA-approved next-generation sequencing assay, xT CDx. This designation, the first of its kind, allows Tempus to offer tumor mutation profiling for patients with solid organ neoplasms. The initial ADLT reimbursement rate is set at $4,500, effective from July 1, 2024, to March 31, 2025. After this period, starting April 1, 2025, CMS will establish a new Medicare rate based on private payer data. Ezra Cohen, Chief Medical Officer of Oncology at Tempus, stated this milestone reflects their commitment to improving patient care through precision medicine.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.92%
Tags
none
-
Rhea-AI Summary

Tempus AI has received FDA 510(k) clearance for its Tempus ECG-AF, an AI-based algorithm aimed at identifying patients at increased risk of atrial fibrillation/flutter (AF). This clearance is significant as it marks the first FDA approval for cardiovascular machine learning-based notification software targeting AF. The Tempus ECG-AF device analyzes 12-lead ECG recordings to detect AF risk within the next 12 months in patients aged 65 and older without a prior history of AF. The technology aims to aid physicians in early AF detection, potentially improving treatment outcomes.

The clearance bolsters Tempus' position in AI-driven clinical solutions and heralds the launch of a suite of next-generation cardiovascular diagnostics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.42%
Tags
Rhea-AI Summary

Tempus AI (NASDAQ: TEM) has announced a collaboration with United Therapeutics (UT) to develop AI-based medical device software for early detection of pulmonary hypertension (PH). This fatal heart and lung condition affects around 1% of the population. Despite available treatments, PH diagnosis is typically delayed by over two years. Tempus' AI algorithm, which analyzes ECG results to identify at-risk patients, was presented at the American Thoracic Society International Conference. The algorithm will be deployed in a prospective clinical study at up to 60 centers. Tempus aims to engage with the FDA for regulatory alignment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.38%
Tags
AI
-
Rhea-AI Summary

Tempus AI announced the pricing of its initial public offering (IPO) of 11,100,000 shares of Class A common stock at $37.00 per share.

The gross proceeds are expected to be $410.7 million, before deducting underwriting discounts, commissions, and other expenses.

The underwriters have a 30-day option to purchase an additional 1,665,000 shares.

The shares will trade on the Nasdaq Global Select Market under the ticker symbol "TEM" starting June 14, 2024, with the offering expected to close on June 17, 2024.

Morgan Stanley, J.P. Morgan, and Allen & Company are the lead book-running managers, with BofA Securities and TD Cowen also participating.

Stifel, William Blair, Loop Capital Markets, and Needham & Company are co-managers.

The SEC declared the registration statement effective on June 13, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags

FAQ

What is Tempus AI, Inc.?

Tempus AI, Inc. is a technology company that develops AI-driven solutions to improve healthcare, including the Tempus Platform and Intelligent Diagnostics.

What does the Tempus Platform do?

The Tempus Platform frees healthcare data from silos and makes it useful through an advanced operating system, providing actionable insights for better patient care.

How does Tempus AI use AI in healthcare?

Tempus AI employs advanced AI, including generative AI, in its Intelligent Diagnostics to enhance the accuracy and personalization of laboratory tests.

What are Intelligent Diagnostics?

Intelligent Diagnostics is a suite of AI-driven tools by Tempus AI that improve the precision and personalization of lab tests for better diagnostic outcomes.

What are some recent achievements of Tempus AI?

Recent achievements include advancements in AI algorithms and successful integrations with major healthcare systems, showcasing Tempus AI's innovative edge.

How is Tempus AI financially performing?

Tempus AI has demonstrated robust financial growth and maintained a strong economic foundation, making it an attractive option for investors.

Who are Tempus AI's partners?

Tempus AI collaborates with major healthcare systems and strategic partners to expand its impact and advance its technological solutions.

Why is Tempus AI significant in the healthcare sector?

Tempus AI is significant due to its innovative use of AI to revolutionize diagnostics and data accessibility, leading to improved healthcare outcomes.

What is the importance of the operating system in the Tempus Platform?

The operating system in the Tempus Platform ensures that liberated healthcare data is accessible and useful, facilitating better decision-making in healthcare.

How can I stay updated on Tempus AI's latest news?

To stay updated on Tempus AI's latest news and developments, follow reliable sources and platforms that provide detailed information about the company's performance.

Tempus AI, Inc

Nasdaq:TEM

TEM Rankings

TEM Stock Data

6.82B
159.79M
55.94%
5.86%
Health Information Services
Healthcare
Link
United States of America
Chicago